All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Iduronate 2-sulfatase (IDS, EC 3.1.6.13) is a lysosomal enzyme that catalyses the hydrolysis of sulfated esters at the non-reducing-terminal iduronic acids in the glycosaminoglycans (GAGs) heparan sulfate and dermatan sulfate. A deficiency of IDS activity results in systemic accumulation of GAGs, leading to a rare metabolic disease, mucopolysaccharidosis type II (MPS II, OMIM 309900), which is also known as Hunter syndrome \[[@pone.0163964.ref001]\]. Patients with MPS II typically exhibit systemic manifestations including a short stature, a specific facial appearance, dysostosis multiplex, a thick skin, inguinal hernia, hepatosplenomegaly, hearing difficulty, an ophthalmic problem, a respiratory defect, heart disease, and occasional neurologic involvement. However, this disease exhibits a wide range of clinical phenotypes from the "severe form" with progressive clinical deterioration to the "attenuated form" without mental retardation.

Enzyme replacement therapy (ERT) involving recombinant human IDS is approved in many countries for treatment of MPS II patients. As recent studies demonstrated that ERT improved the manifestations of MPS II, especially when it was started at an early age \[[@pone.0163964.ref002]--[@pone.0163964.ref005]\], an early diagnosis and clinical phenotype determination are becoming more and more important for predicting the prognoses of patients and a proper therapeutic plan.

The IDS gene is located at the Xq27/28 boundary \[[@pone.0163964.ref006]\], and contains nine exons spread over 24 kb \[[@pone.0163964.ref007],[@pone.0163964.ref008]\]. It has been reported that 2.3 kb-IDS cDNA encodes a polypeptide of 550 amino acids showing high homology with the sulfatase protein family \[[@pone.0163964.ref008],[@pone.0163964.ref009]\]. The synthesized IDS requires post-translational modification including removal of the signal sequence peptide, glycosylation, phosphorylation, proteolysis, and conversion of C84 to the catalytic formylglycine: the 76 kDa precursor is processed through intermediates to the 55 kDa and 45 kDa mature forms \[[@pone.0163964.ref010]\]. So far, at least 530 genetic mutations responsible for MPS II have been identified, and it is known that gross alterations lead to the severe form. However, missense mutations comprising about 30% of the MPS II mutations result in heterogeneous phenotypes ranging from the severe to the attenuated form.

As to human IDS, no crystal structure has been reported, and a few structural models have been constructed by means of homology modeling using crystal structure information of other sulfatases including arylsulfatase A and arylsulfatase B as templates \[[@pone.0163964.ref011]--[@pone.0163964.ref014]\]. In those studies, some missense mutations were found to be localized on the predicted IDS structure and the effects of amino acid substitutions were discussed. But the number of mutations discussed was very small.

In this study, we built a new structural model of human IDS by means of the homology modeling and molecular dynamics methods, and predicted structural changes in IDS caused by 131 amino acid substitutions responsible for MPS II, and examined the relationship between the mutant IDS structures and the respective clinical phenotypes.

Methods {#sec002}
=======

Missense mutations in the *IDS* gene {#sec003}
------------------------------------

In this study, we analyzed 131 missense mutations in the *IDS* gene for which the MPS II phenotypes have been clearly described (67 severe and 64 attenuated). These missense mutations, the respective phenotypes, and the references are summarized in **[Table 1](#pone.0163964.t001){ref-type="table"}**, and other missense mutations in the *IDS* gene that were excluded in this analysis are summarized in **[S1 Table](#pone.0163964.s001){ref-type="supplementary-material"}**.

10.1371/journal.pone.0163964.t001

###### IDS mutations, phenotypes, references, and structural characteristics for mutant IDS proteins.

![](pone.0163964.t001){#pone.0163964.t001g}

  Mutation   Phenotype[^\*^](#t001fn001){ref-type="table-fn"}   Numbers of affected atoms   RMSD   ASA   Reference           
  ---------- -------------------------------------------------- --------------------------- ------ ----- ----------- ------- -------------------------------------------------------
  p.D45N     Attenuated                                         30                          40     13    0.04        1       Vafiadaki (1998) Arch Dis Child 79:237
  p.R48P     Attenuated                                         81                          107    0     0.086       30.6    Sukegawa (1995) Hum Mutat 6:136
  p.Y54D     Severe                                             24                          30     0     0.039       126.8   Karsten (1998) Hum Genet 103:732
  p.S61P     Attenuated                                         80                          67     0     0.071       2       Sohn (2012) Clin Genet 81:185
  p.N63D     Attenuated                                         4                           15     0     0.022       53.5    Karsten (1998) Hum Genet 103:732
  p.N63K     Severe                                             28                          43     0     0.038       53.5    Chang (2005) Hum Genet 116:160
  p.L67P     Severe                                             24                          24     0     0.045       3.2     Zhang (2011) PLoS One 6:e22951
  p.A68E     Severe                                             188                         205    0     0.125       2.1     Schroeder (1994) Hum Mutat 4:128
  p.S71R     Severe                                             105                         109    0     0.085       0.2     Li (1999) J Med Genet 36:21
  p.S71N     Attenuated                                         30                          29     0     0.04        0.2     Froissart (1998) Clin Genet 53:362
  p.L72P     Severe                                             64                          83     0     0.07        1.2     Zhang (2011) PLoS One 6:e22951
  p.A79E     Attenuated                                         153                         167    22    0.097       0       Karsten (1998) Hum Genet 103:732
  p.Q80K     Severe                                             203                         199    7     0.103       5.2     Gucev (2011) Prilozi 32:187
  p.P86R     Severe                                             281                         325    9     0.171       0       Hopwood (1993) Hum Mutat 2:435
  p.P86L     Severe                                             114                         118    6     0.096       0       Vafiadaki (1998) Arch Dis Child 79:237
  p.S87N     Attenuated                                         10                          10     2     0.025       0.4     Popowska (1995) Hum Mutat 5:97
  p.R88C     Severe                                             189                         222    29    0.108       0.4     Karsten (1998) Hum Genet 103:732
  p.R88G     Severe                                             159                         212    23    0.097       0.4     Froissart (1998) Clin Genet 53:362
  p.R88H     Severe                                             23                          37     16    0.032       0.4     Karsten (1998) Hum Genet 103:732
  p.R88L     Severe                                             27                          39     5     0.04        0.4     Karsten (1998) Hum Genet 103:732
  p.R88P     Severe                                             40                          63     16    0.051       0.4     Villani (2000) Biochim Biophys Acta 1501: 71
  p.L92P     Severe                                             14                          9      0     0.028       5.4     Popowska (1995) Hum Mutat 5:97
  p.G94D     Attenuated                                         111                         107    0     0.098       0       Hopwood (1993) Hum Mutat 2:435
  p.R95G     Attenuated                                         126                         147    0     0.086       34      Goldenfum (1996) Hum Mutat 7:76
  p.R95T     Attenuated                                         87                          97     0     0.071       34      Moreira da Silva (2001) Clin Genet 60:316
  p.P97R     Severe                                             514                         542    25    0.229       3.6     Sohn (2012) Clin Genet 81:185
  p.L102R    Attenuated                                         129                         142    8     0.127       0       Karsten (1998) Hum Genet 103:732
  p.Y108C    Attenuated                                         0                           0      0     0.002       131     Rathmann (1996) Am J Hum Genet 59:1202
  p.Y108S    Attenuated                                         0                           0      0     0.002       131     Zhang (2011) PLoS One 6:e22951
  p.W109R    Severe                                             76                          98     0     0.054       110.3   Chistiakov (2014) J Genet Genomics 41:197
  p.N115Y    Attenuated                                         56                          45     0     0.093       25.3    Vafiadaki (1998) Arch Dis Child 79:237
  p.S117Y    Severe                                             134                         127    0     0.094       34.6    Kim (2003) Hum Mutat 21:449
  p.Q121R    Severe                                             221                         241    9     0.146       24.6    Froissart (1998) Clin Genet 53:362
  p.E125V    Attenuated                                         6                           2      0     0.015       127.2   Rathmann (1996) Am J Hum Genet 59:1202
  p.T130N    Attenuated                                         0                           0      0     0.006       56.9    Boyadjiev (2012) Mol Genet Metab 105:S22
  p.T130I    Attenuated                                         0                           0      0     0.002       56.9    Zhang (2011) PLoS One 6:e22951
  p.S132W    Severe                                             328                         340    8     0.192       44.8    Jonsson (1995) Am J Hum Genet 56:597
  p.G134R    Severe                                             146                         171    9     0.11        1.4     Rathmann (1996) Am J Hum Genet 59:1202
  p.G134E    Attenuated                                         61                          78     9     0.1         1.4     Amartino (2014) Mol Genet Metab Rep 1:401
  p.K135R    Attenuated                                         54                          41     0     0.047       13.3    Hopwood (1993) Hum Mutat 2:435
  p.K135N    Attenuated                                         28                          38     0     0.033       13.3    Popowska (1995) Hum Mutat 5:97
  p.H138D    Attenuated                                         355                         365    21    0.155       13      Froissart (1998) Clin Genet 53:362
  p.H138R    Severe                                             52                          37     0     0.049       13      Chang (2005) Hum Genet 116:160
  p.G140R    Attenuated                                         244                         296    15    0.18        3.5     Kato (2005) J Hum Genet 50:395
  p.S142F    Severe                                             0                           0      0     0.002       84.8    Chistiakov (2014) J Genet Genomics 41:197
  p.S142Y    Severe                                             0                           0      0     0.003       84.8    Amartino (2014) Mol Genet Metab Rep 1:401
  p.S143F    Severe                                             0                           3      0     0.003       77.3    Vallence (1999) hum mut mutation in brief\#233 online
  p.D148V    Severe                                             71                          70     3     0.072       105.2   Keeratichamroen (2008) J Inherit Metab Dis 31S2:S303
  p.P157S    Severe                                             1                           0      0     0.007       62.6    Amartino (2014) Mol Genet Metab Rep 1:401
  p.H159P    Severe                                             64                          69     4     0.086       46.6    Karsten (1998) Hum Genet 103:732
  p.C171R    Attenuated                                         15                          17     0     0.029       23.4    Kato (2005) J Hum Genet 50:395
  p.N181I    Attenuated                                         1                           0      0     0.009       121.9   Moreira da Silva (2001) Clin Genet 60:316
  p.L182P    Attenuated                                         45                          43     0     0.048       60.6    Isogai (1998) J Inherit Metab Dis 21:60
  p.C184F    Attenuated                                         267                         281    0     0.137       25.8    Rathmann (1996) Am J Hum Genet 59:1202
  p.L196S    Attenuated                                         3                           21     0     0.019       5       Jonsson (1995) Am J Hum Genet 56:597
  p.D198N    Severe                                             53                          99     0     0.062       0.6     Amartino (2014) Mol Genet Metab Rep 1:401
  p.D198G    Attenuated                                         225                         250    9     0.111       0.6     Karsten (1998) Hum Genet 103:732
  p.A205P    Attenuated                                         11                          9      0     0.032       2       Goldenfum (1996) Hum Mutat 7:76
  p.T214M    Severe                                             1                           0      0     0.003       82.4    Amartino (2014) Mol Genet Metab Rep 1:401
  p.L221P    Attenuated                                         37                          46     0     0.059       6.4     Hopwood (1993) Hum Mutat 2:435
  p.G224A    Severe                                             1                           9      0     0.037       3.3     Keeratichamroen (2008) J Inherit Metab Dis 31S2:S303
  p.G224E    Severe                                             40                          56     4     0.065       3.3     Karsten (1998) Hum Genet 103:732
  p.Y225D    Attenuated                                         98                          124    3     0.081       3.4     Sukegawa (1993) 3rd Inter Sympo on MPS, Essen
  p.K227M    Attenuated                                         5                           19     0     0.018       3.6     Isogai (1998) J Inherit Metab Dis 21:60
  p.K227Q    Severe                                             7                           27     0     0.025       3.6     Hopwood (1993) Hum Mutat 2:435
  p.P228L    Attenuated                                         161                         197    18    0.116       0.4     Vafiadaki (1998) Arch Dis Child 79:237
  p.P228A    Attenuated                                         0                           0      0     0.004       0.4     Sohn (2012) Clin Genet 81:185
  p.P228Q    Severe                                             198                         223    12    0.111       0.4     Amartino (2014) Mol Genet Metab Rep 1:401
  p.P228T    Severe                                             20                          19     1     0.039       0.4     Gort (1998) J Inherit Metab Dis 21:655
  p.H229Y    Severe                                             14                          25     4     0.027       15      Jonsson (1995) Am J Hum Genet 56:597
  p.P231L    Attenuated                                         9                           15     0     0.019       26.9    Gort (1998) J Inherit Metab Dis 21:655
  p.R233G    Attenuated                                         9                           17     0     0.021       85      Chistiakov (2014) J Genet Genomics 41:197
  p.K236N    Attenuated                                         19                          26     0     0.027       73.9    Gucev (2011) Prilozi 32:187
  p.P261A    Attenuated                                         47                          43     0     0.077       107.3   Sohn (2012) Clin Genet 81:185
  p.N265I    Attenuated                                         41                          57     0     0.044       0.5     Filocamo (2001) Hum Mutat 18:164
  p.N265K    Severe                                             127                         148    0     0.077       0.5     Chistiakov (2014) J Genet Genomics 41:197
  p.P266R    Severe                                             105                         140    0     0.086       6       Vafiadaki (1998) Arch Dis Child 79:237
  p.W267C    Attenuated                                         54                          54     0     0.057       82.9    Chang (2005) Hum Genet 116:160
  p.Q293H    Attenuated                                         91                          110    0     0.091       0.6     Schroeder (1994) Hum Mutat 4:128
  p.K295I    Severe                                             7                           16     0     0.015       71.2    Amartino (2014) Mol Genet Metab Rep 1:401
  p.S299I    Attenuated                                         141                         172    0     0.088       0       Kim (2003) Hum Mutat 21:449
  p.S305P    Attenuated                                         63                          67     0     0.054       30.7    Brusius-Facchin (2014) Mol Genet Metab 111:133
  p.D308N    Attenuated                                         15                          31     0     0.03        9       Isogai (1998) J Inherit Metab Dis 21:60
  p.D308E    Attenuated                                         43                          42     0     0.054       9       Gort (1998) J Inherit Metab Dis 21:655
  p.T309A    Severe                                             0                           0      0     0.003       55.2    Gort (1998) J Inherit Metab Dis 21:655
  p.G312D    Attenuated                                         23                          25     0     0.034       5.5     Amartino (2014) Mol Genet Metab Rep 1:401
  p.S333L    Severe                                             67                          73     21    0.072       0       Vafiadaki (1998) Arch Dis Child 79:237
  p.D334N    Attenuated                                         22                          23     2     0.034       0.8     Froissart (1998) Clin Genet 53:362
  p.D334G    Severe                                             52                          52     14    0.07        0.8     Li (1996) J Inherit Metab Dis 19:93
  p.H335R    Attenuated                                         42                          49     20    0.049       0.6     Froissart (1998) Clin Genet 53:362
  p.G336E    Severe                                             235                         291    30    0.159       0       Froissart (1998) Clin Genet 53:362
  p.G336V    Severe                                             97                          137    23    0.11        0       Kato(2005) J Hum Genet 50:395
  p.W337R    Attenuated                                         84                          111    18    0.057       0.2     Sukegawa (1995) Hum Mutat 6:136
  p.L339R    Severe                                             37                          69     1     0.042       3.8     Froissart (1998) Clin Genet 53:362
  p.L339P    Severe                                             33                          52     0     0.059       3.8     Amartino (2014) Mol Genet Metab Rep 1:401
  p.G340D    Attenuated                                         20                          17     0     0.024       4.2     Karsten (1998) Hum Genet 103:732
  p.E341K    Severe                                             348                         458    23    0.16        21      Vallence (1999) hum mut mutation in brief\#233 online
  p.H342Y    Attenuated                                         27                          31     0     0.035       5       Vallence (1999) hum mut mutation in brief\#233 online
  p.W345R    Severe                                             25                          32     1     0.03        0.4     Amartino (2014) Mol Genet Metab Rep 1:401
  p.W345K    Attenuated                                         22                          29     1     0.032       0.4     Popowska (1995) Hum Mutat 5:97
  p.A346D    Attenuated                                         100                         115    15    0.083       0       Olsen (1996) Hum Genet 97:198
  p.K347E    Severe                                             249                         251    18    0.109       0.8     Chang (2005) Hum Genet 116:160
  p.K347T    Severe                                             90                          97     16    0.072       0.8     Villani (1997) Hum Mutat 10:71
  p.S349I    Severe                                             70                          95     0     0.072       0.2     Gort (1998) J Inherit Metab Dis 21:655
  p.P358R    Severe                                             320                         323    8     0.123       2       Jonsson (1995) Am J Hum Genet 56:597
  p.L403R    Severe                                             375                         423    35    0.13        5.5     Froissart (1998) Clin Genet 53:362
  p.L410P    Attenuated                                         21                          28     0     0.043       0       Ben Simon-Schiff (1994) Hum Mutat 4:263
  p.C422Y    Attenuated                                         312                         311    9     0.197       0       Gort (1998) J Inherit Metab Dis 21:655
  p.C422G    Attenuated                                         6                           14     0     0.017       0       Hopwood (1993) Hum Mutat 2:435
  p.C432R    Attenuated                                         33                          35     0     0.043       113.1   Lualdi (2006) Biochim Biophys Acta 1762:478
  p.C432Y    Severe                                             0                           0      0     0.002       113.1   Karsten (1998) Hum Genet 103:732
  p.Q465P    Severe                                             85                          114    3     0.09        13.8    Hartog (1999) Hum Mutat 14:87
  p.P467L    Severe                                             92                          109    0     0.101       0.6     Moreira da Silva (2001) Clin Genet 60:316
  p.R468Q    Severe                                             366                         421    17    0.161       0       Vafiadaki (1998) Arch Dis Child 79:237
  p.R468G    Severe                                             61                          100    0     0.063       0       Hopwood (1993) Hum Mutat 2:435
  p.R468L    Severe                                             82                          117    0     0.06        0       Sukegawa (1995) Hum Mutat 6:136
  p.R468P    Severe                                             289                         301    0     0.13        0       Charoenwattanasatien (2012) Biochem Genet 50:990
  p.P469H    Attenuated                                         96                          118    4     0.063       0.2     Jonsson (1995) Am J Hum Genet 56:597
  p.D478G    Attenuated                                         27                          32     0     0.042       54      Schroeder (1994) Hum Mutat 4:128
  p.D478Y    Severe                                             20                          35     0     0.029       54      Karsten (1998) Hum Genet 103:732
  p.P480R    Severe                                             116                         145    0     0.088       42.9    Froissart (1998) Clin Genet 53:362
  p.P480Q    Attenuated                                         39                          47     0     0.07        42.9    Froissart (1998) Clin Genet 53:362
  p.P480L    Attenuated                                         10                          16     0     0.041       42.9    Froissart (1998) Clin Genet 53:362
  p.I485R    Severe                                             170                         236    0     0.141       155.6   Vafiadaki (1998) Arch Dis Child 79:237
  p.I485K    Severe                                             1                           0      0     0.005       155.6   Vafiadaki (1998) Arch Dis Child 79:237
  p.G489D    Severe                                             62                          68     0     0.064       1.8     Chang (2005) Hum Genet 116: 160
  p.Y490S    Attenuated                                         6                           7      0     0.024       74.7    Froissart (1998) Clin Genet 53:362
  p.S491F    Severe                                             135                         167    0     0.081       0.4     Sohn (2012) Clin Genet 81:185
  p.W502C    Severe                                             23                          20     0     0.03        2.2     Vafiadaki (1998) Arch Dis Child 79:237
  p.L522P    Severe                                             55                          65     0     0.063       0.8     Sohn (2012) Clin Genet 81:185
  p.Y523C    Attenuated                                         12                          17     0     0.023       8.4     Jonsson (1995) Am J Hum Genet 56:597

\*Description of the phenotypes is according to the original papers.

Structural modeling of the human wild type IDS protein {#sec004}
------------------------------------------------------

Because no IDS crystal structure has been reported, we built a model of human IDS using homology modeling server I-TASSER ([zhanglab.ccmb.med.umich.edu/](http://zhanglab.ccmb.med.umich.edu/) I-TASSER/) \[[@pone.0163964.ref015]\]. To take protein structure fluctuations into consideration, we conducted molecular dynamics calculations using Gromacs (version 5.0.5) \[[@pone.0163964.ref016]\]. In the simulation, we used the AMBER99sb force field and SPC/E water models. At first, we performed structure optimization using the steepest-descent method. Then, we carried out equilibration in two phases (NVT and NPT ensemble). As the production run, we performed 10ns MD simulation using Parrinello-Rahman pressure coupling and V-rescale temperature simulation. In order to obtain a representative structure, we used the simulated annealing method.

Structural modeling of mutant IDS proteins and calculation of the numbers of atoms influenced by amino acid substitutions responsible for MPS II {#sec005}
------------------------------------------------------------------------------------------------------------------------------------------------

Structural models of mutant human IDS proteins responsible for MPS **II** were built by means of homology modeling using the wild type IDS protein model as a template. For that purpose, we used molecular modeling software TINKER \[[@pone.0163964.ref017]\], and energy minimization was performed, the root-mean-square graduate value being set at 0.05 kcal/mol・Å. Then, each mutant model was superimposed on the wild type IDS structure based on the Cα atoms by the least-square-mean fitting method. We defined that an atom was influenced by an amino acid substitution when the position of the atom in a mutant IDS protein differed from that in the wild type one by more than the cut-off distance (0.15 Å) based on the total root-mean-square distance (RMSD), as described previously \[[@pone.0163964.ref018]\]. We calculated the numbers of influenced atoms in the main chain (the protein backbone: alpha carbon atoms linked to the amino group, the carboxyl one, and hydrogen atoms of the molecule) and the side chain (variable components linked to the alpha carbons of the molecule), and in the active site (D45, D46, C84, K135, and D334). Then, average numbers of influenced atoms were calculated for the severe MPS II group and the attenuated one.

Determination of the RMSD values of all atoms in the mutant IDS proteins {#sec006}
------------------------------------------------------------------------

To determine the influence of each amino acid substitution on the total conformational change in IDS, the RMSD values of all atoms in the mutant IDS proteins were calculated according to the standard method \[[@pone.0163964.ref019]\]. Then, average RMSD values were calculated for the severe group and the attenuated one.

Determination of the accessible surface area (ASA) of the amino acid residues of the IDS protein {#sec007}
------------------------------------------------------------------------------------------------

The ASA of each amino acid residue in the structure of the wild type IDS was calculated using Stride \[[@pone.0163964.ref020]\] to determine the location of the residue in the IDS molecule. Then, the average ASA values of the residues for which substitutions had been identified in the severe group and the attenuated one were calculated.

Statistical analysis {#sec008}
--------------------

Statistical analysis to determine the differences in the numbers of influenced atoms, the RMSD, and the ASA values between the severe MPS II group and the attenuated one was performed by means of Welch's *t*-test, and it was taken that there was a significant difference if p\< 0.05.

Coloring of the atoms influenced by different amino acid substitutions at the same residue on IDS {#sec009}
-------------------------------------------------------------------------------------------------

Coloring of the influenced atoms in the three-dimensional structure of IDS was performed for amino acid substitutions including P480R (phenotype: severe), P480L (phenotype: attenuated), D334G (phenotype: severe), and D334N (phenotype: attenuated) as representatives, based on the distance between the wild type and mutant to determine the influence of the amino acid substitutions geographically and semi-quantitatively according to the method previously described \[[@pone.0163964.ref018]\].

Construction of a database including genotypes, clinical phenotypes, references and mutant IDS structures in MPS II {#sec010}
-------------------------------------------------------------------------------------------------------------------

In order to help researchers and clinicians who study MPS II, we built a database including the genotypes, clinical phenotypes, references, and structures of mutant IDSs, according to the method described previously \[[@pone.0163964.ref021]\].

Results {#sec011}
=======

Structural model of the human IDS protein and locations of the amino acid residues associated with MPS II {#sec012}
---------------------------------------------------------------------------------------------------------

A homology modeling server was used to construct a structural model of the wild type IDS protein. For this calculation, several known structures were used as templates (pdb id: 2w8s, 2vqr, 3b5q, and 2quz). The results of the homology modeling revealed that IDS consists of alpha/beta folds, and that it contains two antiparallel beta-sheets (each sheet has 4 beta strands) with alpha helixes around them. The active site is located in the loop region near the N-terminal antiparallel beta-strand, and the D45, D46, C84, K135 and D334 residues comprising the putative active site \[[@pone.0163964.ref014]\] are indicated (**[Fig 1A](#pone.0163964.g001){ref-type="fig"}**). Then, to elucidate the relationship between the locations of the amino acid substitutions associated with MPS II and the respective phenotypes, we identified the positions of the residues in the wild type IDS protein structure (**[Fig 1B](#pone.0163964.g001){ref-type="fig"}**). The locations of the amino acid residues involved in the substitutions were widely spread over the enzyme molecule.

![Predicted structure of human IDS **(a),** and positions of amino acid residues where substitutions responsible for MPS II have been identified **(b)**. The backbone is displayed as a ribbon model. **(a)** IDS is colored according to the secondary structure. Helices are colored red, sheets blue, and loops gray. The residues comprising the putative active site (D45, D46, C84, K135, and D334) are presented as small dark blue spheres. **(b)** The residues involved in substitutions responsible for MPS II are presented as spheres (severe: magenta, attenuated: blue, and both: green).](pone.0163964.g001){#pone.0163964.g001}

Numbers of atoms influenced by amino acid substitutions associated with MPS II {#sec013}
------------------------------------------------------------------------------

Then, we constructed structural models of the mutant IDS proteins and calculated the number of atoms influenced by the amino acid substitution for each mutant model. The results are summarized in **[Table 1](#pone.0163964.t001){ref-type="table"}**. In the severe phenotypic group, the average values (± standard deviation, SD) for the influenced atoms in the main chain and the side chain regarding the amino acid substitutions were 106 (± 113) and 124 (± 125), respectively. In particular, 42 of the 67 severe cases (63%) had 50 atoms or more influenced in the main chain. On the other hand, in the attenuated group, the averages (± SD) of the influenced atoms in the main chain and side chain were 63 (± 78) and 71 (± 84), respectively. Notably, regarding the main chain atoms, 39 of the 64 of the attenuated cases (61%) had 49 atoms or less affected. **[Fig 2](#pone.0163964.g002){ref-type="fig"}** shows the means ± SD and boxplots of the influenced atoms of the main chain (**[Fig 2A](#pone.0163964.g002){ref-type="fig"}**) and the side chain (**[Fig 2B](#pone.0163964.g002){ref-type="fig"}**) in the severe MPS II group and the attenuated one. Welch's *t*-test revealed that there was a significant difference in the numbers of influenced atoms in both the main chain and the side chain (p\<0.05) between the severe and attenuated groups. These results indicate that the structural changes caused by the amino acid substitutions responsible for severe MPS II were generally larger than those for attenuated MPS II. As to the influence of amino acid substitutions on the active site, the atoms of the residues comprising the putative active site were affected in 31 of the 67 severe cases (46%) and 17 of the 64 attenuated ones (27%).

![Boxplots of numbers of atoms affected by amino acid substitutions in the main chain **(a)** and the side chain **(b)**, RMSD values between mutant and wild type IDS proteins **(c)**, and ASA of amino acid residues where substitutions responsible for MPS II occur **(d)**. *Severe*: Severe group. *Attenuated*: Attenuated group.](pone.0163964.g002){#pone.0163964.g002}

RMSD values between mutant IDS proteins and the wild type {#sec014}
---------------------------------------------------------

To clarify the total structural change caused by each amino acid substitution, the RMSD value between the mutant IDS protein and the wild type was calculated, and the results are summarized in **[Table 1](#pone.0163964.t001){ref-type="table"}**. The means ± SD and boxplots of RMSD values for the severe MPS II group and attenuated one are shown in **[Fig 2C](#pone.0163964.g002){ref-type="fig"}**. The average RMSD values (± SD) for the severe and attenuated groups were 0.074 (± 0.050) and 0.056 (± 0.043) Å, respectively. The Welch's *t*-test showed that there was a significant difference in RMSD between the severe MPS II group and the attenuated one (p\<0.05). These results indicate that structural changes in the severe MPS II group were larger than those in the attenuated one.

ASA of the amino acid residues associated with MPS II mutations {#sec015}
---------------------------------------------------------------

To identify the locations of the residues associated with MPS II mutations in the IDS protein, the ASA values of the residues in the wild type structure were calculated and the results are summarized in **[Table 1](#pone.0163964.t001){ref-type="table"}**. **[Fig 2D](#pone.0163964.g002){ref-type="fig"}** shows the means ± SD and boxplots of ASA for the severe group and the attenuated one. In the severe MPS II group, the average ASA value (± SD) was 25.2 (± 40.8) Å^2^. On the other hand, in the attenuated MPS II group, it was 27.9 (± 38.7) Å^2^. The results of the Welch's *t*-test (p\> 0.05) showed that there was no significant difference between the two groups.

Effects of different substitutions at the same residue on the IDS structure and coloring of atoms affected in the molecule {#sec016}
--------------------------------------------------------------------------------------------------------------------------

We next examined the effects of different substitutions at the same residue on the structural changes in the molecule and expression of the clinical phenotypes. There are at least 12 residues in the amino acid sequence of IDS at which different substitutions lead to different phenotypes (**[Table 1](#pone.0163964.t001){ref-type="table"}**). For seven of those residues (N63, S71, G134, K227, N265, D334, and D480), the RMSD value and the number of affected atoms for the severe group were larger than those for the attenuated one. On the other hand, for 3 residues (H138, D198, and C432), the RMSD value and the number of affected atoms for the attenuated group were larger than those for the severe one. As to the other 2 residues (P228 and W345), it could not be determined for which phenotype the RMSD value and the number of affected atoms were larger than the other. Then, we examined the structural changes in IDS caused by P480R (phenotype: severe), P480L (phenotype: attenuated), D334G (phenotype: severe), and D334N (phenotype: attenuated) by means of coloring of the atoms affected. P480 is located near the molecular surface, and far from the active site. P480R is thought to cause a large structural change around the substituted residue, although it does not affect the active site, leading to the severe phenotype. The structural change caused by P480L is small and the influenced atoms are limited, leading to the attenuated phenotype (**[Fig 3A](#pone.0163964.g003){ref-type="fig"}**). On the other hand, D334 is a residue comprising the active site, and the D334G and D334N substitutions are both thought to directly affect the structure of the active site. The structural change in the former is larger than that in the latter, leading to the difference in phenotype (**[Fig 3B](#pone.0163964.g003){ref-type="fig"}**)

![Coloring of the atoms influenced by amino acid substitutions, **(a)** P480R and P480L, and **(b)** D334G and D334N, in the three-dimensional structure of IDS. The backbone of IDS is shown as a blue ribbon model. The influenced atoms are presented as spheres. The colors of the influenced atoms show the distances between the wild type and mutant proteins as follows: 0.15Å ≤ cyan \< 0.30 Å, 0.30 Å ≤ green \< 0.45Å, 0.45 Å ≤ yellow \< 0.60Å, 0.60 Å ≤ orange\< 0.75Å, and 0.75Å ≤ red.](pone.0163964.g003){#pone.0163964.g003}

Database of the genotypes, clinical phenotypes, references and mutant IDS structures in MPS II {#sec017}
----------------------------------------------------------------------------------------------

We developed a database including the genotypes, clinical phenotypes, references and mutant IDS structures responsible for MPS II ([mps2-database.org](http://mps2-database.org)) (**[Fig 4A](#pone.0163964.g004){ref-type="fig"}**). The database provides readers with information on 530 MPS II mutations, which include 161 missense ones. The database is equipped with several tools. A text search tool is provided for searching the given text in selected fields of the database. Furthermore, using the control table option, users can search for MPS II mutations connected with specific phenotypes. A structural viewer is included in the database, which allows users to display the three-dimensional structures of the molecules using Jmol (**[Fig 4B](#pone.0163964.g004){ref-type="fig"}**). Furthermore, users can use many options for visualizing the structures of mutant IDS proteins.

![The list of MPS II gene mutations **(a),** and coloring of a mutant IDS protein with p.A68E **(b)** in the database ([mps2-database.org](http://mps2-database.org)).](pone.0163964.g004){#pone.0163964.g004}

Discussion {#sec018}
==========

Structural information on defective IDS proteins is important to elucidate the pathogenesis of MPS II, and is also useful for understanding the basis of the disease in each patient and for preparing a proper therapeutic plan for him or her.

So far, several structural models of the wild type IDS have been reported \[[@pone.0163964.ref011]--[@pone.0163964.ref014]\]. Unfortunately, they have not been registered in the Protein Data Bank (pdb), and thus we could not precisely compare our new model with them. However, as far as we examined the figures in their reports, it seems that there are no large differences in the whole structure between their models and ours, but there are small differences between them, i.e., in the loop regions of the molecule.

Regarding the locations of residues involved in amino acid substitutions, Kato et al. examined eight cases (phenotypes: 4 severe and 4 attenuated), and reported that the mutations found in the severe phenotype probably undergo direct interactions with the active site residues or break the hydrophobic core region of IDS, whereas residues of the missense mutations found in the attenuated phenotype were located in the peripheral region \[[@pone.0163964.ref013]\]. But our study, in which 131 missense mutations (phenotypes: 67 severe and 64 attenuated) were analyzed, revealed that there was essentially no difference in the localization of amino acid substitutions between the severe group and the attenuated one (**Figs [1B](#pone.0163964.g001){ref-type="fig"} and [2D](#pone.0163964.g002){ref-type="fig"}**).

In order to examine structural changes caused by the amino acid substitutions we calculated the numbers of atoms affected and the RMSD values. The results revealed that structural changes in the severe group were generally larger than those in the attenuated one (**[Fig 2A, 2B and 2C](#pone.0163964.g002){ref-type="fig"}).**

We examined structural changes caused by different substitutions at the same residue in the amino acid sequence of IDS and the phenotypes. Furthermore, structural changes caused by P480R, P480L, D334G, and D334N were examined as representative cases by coloring of the atoms affected in IDS. The results revealed that the structural changes influenced the disease progression.

A lot of expression studies have been performed, and the results revealed that the "attenuated" mutants expressed the precursor and small amounts of the mature IDS, resulting in residual enzyme activity, although the "severe" mutants expressed the precursor but no mature IDS, resulting in almost completely deficient enzyme activity \[[@pone.0163964.ref014],[@pone.0163964.ref022]--[@pone.0163964.ref025]\]. Considering these findings, the majority of the "severe" missense mutants cause large structural changes and defects of the molecular folding, leading to rapid degradation and/or insufficient processing. On the other hand, the "attenuated" missense mutants generally cause small structural changes and moderate folding defects, leading to partial degradation of the enzyme protein and residual activity. Some mutants may directly affect the active site, leading to a decrease in enzyme activity according to the degree of the structural changes.

Finally, we built a database of IDS gene mutations responsible for MPS II, clinical phenotypes, references, and predicted structures of mutant IDSs. This database can be accessed via the Internet, being user-friendly.

In conclusion, we constructed structural models of the wild type and mutant IDS proteins by means of the latest homology modeling techniques, and showed the correlation between the structural changes and clinical phenotypes. This database based on the results of a structural study will help investigators and clinicians who study MPS II.

Supporting Information {#sec019}
======================

###### Mutations which were excluded in the analysis.

(XLSX)

###### 

Click here for additional data file.
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